Language Selection

Get healthy now with MedBeds!
Click here to book your session

Protect your whole family with Orgo-Life® Quantum MedBed Energy Technology® devices.

Advertising by Adpathway

         

 Advertising by Adpathway

Adding Ociperlimab to Tislelizumab Fails to Improve Advanced Esophageal Cancer Survival

1 hour ago 10

PROTECT YOUR DNA WITH QUANTUM TECHNOLOGY

Orgo-Life the new way to the future

  Advertising by Adpathway

In the randomized phase II AdvanTIG-203 trial, adding the investigational anti-TIGIT monoclonal antibody ociperlimab to the anti-PD-1 antibody tislelizumab did not significantly improve objective response rates or survival outcomes compared with tislelizumab alone in patients with advanced esophageal squamous cell carcinoma whose tumors expressed PD-L1 with a tumor area positivity score of ten percent or greater. Investigator-assessed objective response rate reached 30.6 percent with the combination versus 20.6 percent with tislelizumab plus placebo, yielding a stratified risk difference of 9.9 percent with a 95 percent confidence interval spanning minus 5.4 percent to 25.3 percent and a two-sided stratified p-value of 0.2114. Because this primary endpoint did not cross the prespecified significance threshold or the planned efficacy boundary of a greater than 16.3 percent difference, formal hypothesis testing for secondary endpoints was not performed. The trial investigators concluded that adding ociperlimab to tislelizumab is not supported by current evidence in recurrent or metastatic second-line disease.

Esophageal squamous cell carcinoma represents approximately eighty percent of all esophageal malignancies diagnosed globally, carrying a poor prognosis reflected in an estimated five-year overall survival rate of only sixteen percent. For patients with locally advanced resectable tumors, established standard care consists of neoadjuvant chemoradiotherapy followed by surgical resection with or without adjuvant chemotherapy, or exclusive chemoradiotherapy accompanied by surveillance and salvage esophagectomy when complete response is absent or recurrence occurs. Guidelines from the European Society for Medical Oncology currently recommend first-line systemic chemotherapy combined with programmed cell death protein 1 inhibitors, including pembrolizumab, nivolumab, or tislelizumab, alongside second-line nivolumab or tislelizumab for patients who have not previously received checkpoint inhibition. In the United States, several programmed cell death protein 1 inhibitors have gained regulatory approval across first-line and second-line settings. Nonetheless, survival outcomes remain poor across this patient population, sustaining an urgent clinical need for novel therapeutic regimens.

To address this therapeutic plateau, oncology researchers evaluated combinatorial regimens aimed at simultaneously targeting distinct inhibitory pathways within the tumor microenvironment. Ociperlimab is an engineered humanized Fc-intact immunoglobulin G1 monoclonal antibody designed to bind with high specificity and affinity to the T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain, known as TIGIT. This immune checkpoint receptor is naturally expressed across cytotoxic T cells, regulatory T cells, and natural killer cells. Tislelizumab is an approved anti-PD-1 monoclonal antibody that prevents programmed cell death protein 1 from engaging its immunosuppressive ligands, thereby restoring cytotoxic T-cell activation. Preclinical investigations established that TIGIT and PD-1 are frequently co-expressed on tumor-infiltrating CD8-positive T cells and coordinate downstream signaling through the receptor CD226. Laboratory studies suggested that dual checkpoint blockade could relieve complementary mechanisms of immune suppression, establishing the scientific rationale for evaluating ociperlimab as the second anti-TIGIT agent tested in clinical development for advanced esophageal squamous cell carcinoma.

The AdvanTIG-203 study was executed as an international, multicenter, randomized, investigator- and patient-blinded, sponsor-unblinded phase II clinical trial conducted across participating medical centers in China, France, the Republic of Korea, Russia, Spain, Taiwan, and Thailand under registry NCT04732494. Investigators enrolled adult patients aged eighteen years or older with histologically confirmed esophageal squamous cell carcinoma who demonstrated disease progression during or following one prior systemic treatment line for unresectable, locally advanced, recurrent, or metastatic cancer. Key inclusion criteria mandated measurable lesions according to Response Evaluation Criteria in Solid Tumors version 1.1, an Eastern Cooperative Oncology Group performance status score of zero or one, and central laboratory verification of PD-L1 expression demonstrating a tumor area positivity score of at least ten percent. Patients were excluded if they had received prior therapy targeting PD-1, PD-L1, PD-L2, TIGIT, or other checkpoint pathways, or if they had participated in earlier clinical trials testing ociperlimab or tislelizumab.

Between March 31, 2021, and December 26, 2023, investigators randomly assigned 125 eligible patients in an equal one-to-one ratio using permuted block randomization stratified by performance status, number of metastatic organ sites, and geographic region. Arm A comprised 62 patients assigned to receive intravenous ociperlimab at a dose of 900 milligrams together with intravenous tislelizumab at 200 milligrams every three weeks, while Arm B comprised 63 patients assigned to receive intravenous placebo plus intravenous tislelizumab at 200 milligrams every three weeks. While baseline demographics, performance status, and metastatic anatomical sites were generally balanced across the two study arms, several notable imbalances emerged between cohorts. Specifically, patients allocated to Arm A exhibited a higher median baseline target lesion sum of diameters of 45.6 millimeters compared with 31.0 millimeters in Arm B. Furthermore, high PD-L1 expression with a tumor area positivity score of twenty-five percent or greater appeared in 54.8 percent of Arm A compared with 38.1 percent of Arm B.

At the final analysis for objective response with a cutoff date of February 1, 2023, investigator assessment confirmed an objective response rate of 30.6 percent in Arm A, comprising two complete responses representing 3.2 percent and seventeen partial responses representing 27.4 percent. In comparison, Arm B demonstrated an investigator-assessed objective response rate of 20.6 percent, reflecting two complete responses representing 3.2 percent and eleven partial responses representing 17.5 percent. Evaluation by an independent review committee yielded aligned outcomes, recording an objective response rate of 32.3 percent in Arm A versus 25.4 percent in Arm B, with a stratified risk difference of 6.6 percent and a 95 percent confidence interval from minus 9.2 percent to 22.5 percent. Among responding patients, investigator-assessed median duration of response reached 14.6 months in Arm A and was not reported in Arm B, while disease control rates reached 61.3 percent and 58.7 percent, and clinical benefit rates reached 33.9 percent and 30.2 percent, respectively.

At the final overall survival data cutoff on December 26, 2023, median study follow-up was 10.0 months for Arm A and 7.8 months for Arm B. The median overall survival reached 10.2 months with a 95 percent confidence interval of 7.9 to 19.5 months in the ociperlimab combination arm, compared with 9.3 months with a confidence interval of 6.4 to 14.8 months in the placebo plus tislelizumab arm. This generated a stratified hazard ratio of 0.92 with a 95 percent confidence interval from 0.58 to 1.45 and a stratified log-rank one-sided p-value of 0.3620. Investigator-assessed median progression-free survival was 3.4 months in both treatment arms, yielding a stratified hazard ratio of 1.07 with a confidence interval spanning 0.71 to 1.61. Investigators initially planned to enroll 280 patients, but widespread adoption of front-line checkpoint inhibitors reduced the eligible population, leading to a sample size reduction to 120 patients while maintaining eighty percent power to detect a twenty-four percent response difference.

The overall safety evaluation demonstrated that adding ociperlimab to tislelizumab was generally well-tolerated, displaying a toxicity profile consistent with the known effects of both therapeutic agents and underlying disease comorbidities. Over ninety percent of patients in each treatment cohort experienced at least one treatment-emergent adverse event, while treatment-related adverse events occurred in 66.1 percent of patients in Arm A and 69.8 percent in Arm B. The most frequent treatment-related adverse events were hypothyroidism, observed in 17.7 percent of Arm A and 15.9 percent of Arm B, anemia, seen in 11.3 percent versus 11.1 percent, and rash, occurring in 11.3 percent versus 3.2 percent. Grade three or higher treatment-related adverse events occurred in 25.8 percent of Arm A patients and 20.6 percent of Arm B patients, most commonly pneumonia, decreased lymphocyte counts, pneumonitis, and anemia. Serious treatment-related events occurred in 21.0 percent of Arm A and 20.6 percent of Arm B, while two fatal treatment-related events involved an acquired tracheoesophageal fistula and an unknown cause.

Exploratory biomarker evaluations conducted on pre-treatment tumor tissue using immunohistochemistry and RNA sequencing provided valuable insights into biological correlates of response. Analysis of programmed death-ligand 1 tumor area positivity and TIGIT protein expression demonstrated limited correlation with objective response gains and no association with survival improvements in Arm A relative to Arm B, mirroring observations from the CITYSCAPE trial. In contrast, transcriptome profiling evaluated through single-sample gene set enrichment analysis indicated that patients possessing an inflamed tumor microenvironment—defined by enriched natural killer cell, T-cell, dendritic cell, macrophage, and B-cell signatures—derived superior clinical outcomes from ociperlimab plus tislelizumab. Natural killer cell signature scores and single-gene expression exhibited statistical trends of positive association with objective response, overall survival, and progression-free survival in Arm A, suggesting that natural killer cell activation facilitated through TIGIT blockade and Fc-gamma receptor engagement may represent an important biological driver of dual checkpoint efficacy.

In discussing the trial findings, the authors highlighted biological and clinical factors that may explain why adding ociperlimab failed to provide statistically significant efficacy gains in this setting. Esophageal squamous cell carcinoma exhibits relatively low TIGIT expression and high molecular heterogeneity, while widespread CD155 expression on tumor cells and macrophages can engage alternative inhibitory receptors that maintain immunosuppression despite TIGIT blockade. Additionally, higher baseline target lesion tumor burden in Arm A may have attenuated therapeutic responsiveness. These observations contrast with front-line trials such as SKYSCRAPER-08 and MORPHEUS-EC, which demonstrated clinical gains with anti-TIGIT tiragolumab plus atezolizumab and chemotherapy; however, those regimens evaluated untreated patients in combination with cytotoxic chemotherapy rather than second-line chemotherapy-free combinations. The authors concluded that current evidence does not support adding ociperlimab to tislelizumab in second-line recurrent or metastatic disease, noting that future research should focus on earlier treatment lines, combinations with chemoradiotherapy, and prospectively selected biomarker-enriched patient cohorts exhibiting natural killer cell infiltration.

Subject of Research: Phase II evaluation of ociperlimab plus tislelizumab in advanced esophageal squamous cell carcinoma

Article Title: Ociperlimab and tislelizumab in advanced esophageal squamous cell carcinoma (AdvanTIG-203): a phase II study

Article References: Wang, F., Lin, C.-Y., Sun, J.-M., Lu, C.-H., Zhu, X., Chen, Z., Zhao, Q., Kim, I.-H., Pan, Y., Zhang, J., Chen, Z., Tougeron, D., Kim, S.-B., Van Cutsem, E., Zaanan, A., Rivera, F., Dechaphunkul, A., Zuo, Y., Wan, Q., … Xu, R.-H. (2026). Ociperlimab and tislelizumab in advanced esophageal squamous cell carcinoma (AdvanTIG-203): a phase II study. Nature Communications, 17(1), Article 10964. https://doi.org/10.1038/s41467-026-77705-8

Image Credits: AI Generated

DOI: 10.1038/s41467-026-77705-8

Keywords: esophageal squamous cell carcinoma, ociperlimab, tislelizumab, AdvanTIG-203, TIGIT inhibition, PD-1 blockade, phase II clinical trial, objective response rate, overall survival, progression-free survival, tumor area positivity, immune checkpoint inhibitors, natural killer cell signature, tumor microenvironment, treatment-emergent adverse events, CD226 pathway, immunotherapy resistance, second-line cancer therapy

Read Entire Article

         

        

Start the new Vibrations with a Medbed Franchise today!  

Protect your whole family with Quantum Orgo-Life® devices

  Advertising by Adpathway